The site will be unavailable from 11:00 PM GMT on Tuesday, 21 July 2026, until 4:00 AM GMT on Wednesday, 22 July 2026, due to scheduled maintenance.

anamorelin

This is a plain language summary of a clinical research study. The study waslooking the effects of a drug called anamorelin for Japanese people withadvanced non-small cell lung cancer (often shortened to NSCLC) who alsohad a condition called cachexia. People with cachexia have a loss of appetite,severe weight loss, loss of body fat and loss of muscle mass (called musclewasting). Cachexia is common in many chronic (long term) diseases, such ascancer and can lead to a decrease in a person's ability to do everyday tasks(called functional strength). Cachexia can negatively affect a person's qualityof life and increases the risk of serious side effects during chemotherapy.Anamorelin is a drug that has been shown in previous research studies to improve appetite and increase lean body mass(the total weight of the body, not counting fat) and overall body weight. In this study, participants were given anamorelin(100 mg daily) for 12 weeks.

26th Jun 2024

Anamorelin for the treatment of Japanese people with non-small cell lung cancer and cachexia: A plain language summary